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Abstract
Background Gastroesophageal reflux (GER) causes
injury of the esophageal squamous epithelium, a condition
called reflux esophagitis. The sequence reflux-esophagitis-
intestinal metaplasia-dysplasia-invasive cancer is widely
accepted as the main adenocarcinogenetic pathway in the
esophagus; however, the mechanisms of this progression
need to be better defined.
Aims We evaluated COX-2 expression and activity in
biopsies from patients affected with GER, and these
parameters have been correlated with the stage of the dis-
ease, ceramide expression, apoptotic process, and angio-
genesis. The effects of celecoxib on bile acid- and EGF-
induced mucosal proliferation, apoptosis and angiogenesis
have been also investigated.
Methods Four groups of patients were distinguished: non
esophagitis, non erosive esophagitis, erosive esophagitis,
and Barrett’s esophagus. COX-2 expression, basal PGE2
levels, proliferative activity, VEGF expression and apop-
tosis were evaluated in esophageal biopsies.
Results COX-2 expression, basal PGE2 levels, prolifera-
tive activity, VEGF expression and apoptosis progressively
increase from non esophagitis patients to patients with non
erosive and erosive esophagitis, to those with BE. Incu-
bation of the cells with DCA/EGF increases PGE2 pro-
duction, proliferative activity and VEGF production,
effects prevented by celecoxib pretreatment. Ceramide
expression increased from non esophagitis patients to
patients with non erosive and erosive esophagitis, and
decreased in BE; caspase-3 activity progressively
decreased from non esophagitis to BE patients, suggesting
an impairment of the apoptotic process with disease
progression.
Conclusion These results stand for a close relationship
between progression of initial steps of gastroesophageal
reflux disease (GERD) and COX-2, proliferative activity
and EGF/VEGF expression and could have implications in
GERD treatment in order to prevent its neoplastic
evolution.
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Introduction
Two isoforms of cyclooxygenase enzyme (COX) have
been identified. COX-1 is considered a housekeeping gene
and is constitutively expressed in most normal tissues,
whereas COX-2 is an inducible enzyme, which can be
rapidly induced by cytokines, inflammatory mediators,
growth factors and tumour promoters and is related to
human inflammatory diseases and carcinogenesis in dif-
ferent tissues [1–5]. A large body of evidence suggests that
induction of COX-2 plays a pivotal role in cancer devel-
opment by promoting cell proliferation, decreasing apop-
tosis rate, stimulating angiogenesis and increasing invasive
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and metastatic potential of the primary tumour [6–9]. A
role of COX-2 in carcinogenesis is also indirectly sup-
ported by a wealth of epidemiological data which have
shown an association of the long-term use of non steroidal
anti-inflammatory drugs (NSAIDs) with a decreased inci-
dence of colorectal, gastric and oesophageal cancers [10].
The mechanism by which NSAIDs exert this possible
cancer-preventing effect remains unclear; however, it is
well known that the target of these drugs is COX and its
effects on the metabolism of arachidonic acid to the various
biologically active prostaglandins [11].
Gastroesophageal reflux (GER) often causes peptic
injury and inflammation of the esophageal squamous epi-
thelium, a condition called reflux esophagitis. Esophagitis
in most cases heals through the regeneration of squamous
cells in the distal oesophagus. Conversely, in some patients
esophagitis heals through a columnar-metaplastic process,
which seems to represent a temptatively protective reaction
to reflux injury since the metaplastic epithelium is more
resistant to the noxious agents than the native tissue. In a
minority of these cases intestinal-type columnar cells are
represented; this condition is called Barrett’s esophagus
(BE) and represents the most common esophageal pre-
cancerous lesion.
The sequence of events—reflux-esophagitis-intestinal
metaplasia-dysplasia-invasive cancer—is widely accepted
as the main carcinogenetic pathway in the esophagus.
However, the fine mechanisms which underlie this pro-
gression need to be defined. In this respect, COX-2 has
been widely studied and its involvement in some of the
different steps of the sequence deeply investigated. It has
been recently shown in ex vivo experiments that reflux
components, acid and/or ‘‘alkaline’’ can affect COX-2
expression in isolated cells from BE and a relationship
between COX-2 induction, dysplasia and adenocarcinoma
has also been reported [12]. Moreover, in rats COX-2
inhibitors reduce inflammation and tendency to develop
reflux-induced adenocarcinoma [13]. Clinical data suggest
that alterations in the susceptibility to apoptosis underlie
the neoplastic progression of Barrett’s esophagus. In fact,
in biopsy samples of Barrett’s epithelium, altered staining
for the antiapoptotic protein Bcl-2 and Bcl-xL has been
found as metaplasia progresses through dysplasia to ade-
nocarcinoma [14]. Moreover, COX-produced prostanoids
have been shown to affect ceramide, an ubiquitous sphin-
golipid messenger that plays an important role in inflam-
mation and in control of tumour cell fate [15].
In man, the only unexplored aspect of COX-2 in
esophageal adenocarcinogenesis is represented by the ear-
liest steps of the process and concerns the role of COX-2
induction, in the step from GER to esophagitis. In the
present study we evaluated COX-2 expression and activity
in biopsies of patients affected with gastroesophageal
reflux disease (GERD) and these parameters were corre-
lated with the stage (particularly the first steps) of the
disease and with the apoptotic process and angiogenesis.
Moreover, apoptosis, angiogenesis and the effects of a
COX-2 inhibitor on bile acid and EGF-induced mucosal
proliferation were also investigated.
Methods
Patients and Tissue Collection
Thirty-three patients (20 males; 13 females; median age
57.78, age range 21–81 years) undergoing upper endos-
copy due to reflux symptoms (heartburn and/or regurgita-
tion) and/or previous documented diagnosis of GERD were
included in the study (Table 1). None of the patients had
taken either NSAIDs or proton pump inhibitors (PPIs) in
the last 2 months before endoscopy. All of them were
thoroughly informed about the study and gave their written
consent for the investigation according to the guidelines of
the Ethical Committee of the University of Florence-Car-
eggi General Hospital.
In each of the patients three adjacent biopsy samples were
taken in the oesophagus immediately above the gastro-
esophageal junction by means of grasp forceps during the
endoscopic examination. One of the samples was fixed in
4 % formaldehyde for conventional histological and
immunohistochemical evaluation. The two other biopsies
were divided in half using an aseptic technique andwashed in
cold phosphate buffered saline (PBS). They were immedi-
ately frozen at -80 "C until use for molecular analysis.
Table 1 Characteristics of study cohort (33 patients)
Characteristic Number (%)
Gender
Male 20 (60.6)
Female 13 (39.4)
Endoscopic evidences
Cardial incompetence 8 (24.2)
Pyloric incompetence 7 (21.2)
Hiatal hernia 8 (24.2)
Metaplastic columnar epithelium 13 (39.4)
Gastritis 2 (6.1)
Esophagitis 7 (21.2)
Reflux induced micropapilloma 1 (3.0)
Histopathological analysis (grade of esophagitis)
Non esophagitis 5 (15.2)
Non erosive esophagitis 11 (33.3)
Erosive esophagitis 11 (33.3)
Barrett’s esophagus 6 (18.2)
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Histopathology
The formalin-fixed biopsies were routinely processed,
paraffin embedded and stained with hematoxylin and eosin
in order to evaluate esophagitis grading and BE using a
standard light microscope. The findings of one or more
alterations such as basal cell hyperplasia, elongation of the
papillae, dilatation of the intercellular spaces, and scattered
intraepithelial eosinophils were identified as macroscopic
esophagitis without erosions. The finding of erosions or
ulcers of the squamous epithelium, with or without intra-
epithelial neutrophils was identified as microscopic erosive
esophagitis. For the diagnosis of BE it was considered
mandatory that the histological presence of intestinal
metaplasia occurred in an endoscopically visible columnar-
lined oesophagus. Patients with none of the just mentioned
histological characteristics were considered as patients
without histological esophagitis although symptomatic for
GER.
Immunostaining for COX-2, MIB-1
Immunohistochemical studies were performed on 4-lm
representative paraffin embedded tissue sections from each
case, using the streptavidin–biotin immunoperoxidase
complex method. Endogenous peroxidase activity was
blocked by immersion in 3 % (v/v) hydrogen peroxide for
20 min. Sections were pre-treated in a microwave oven for
15 min in 10 mmol/L citrate buffer (pH 6.0) before
immunostaining. The following antibodies were used:
polyclonal antibody anti-COX-2 (Santa Cruz Biotechnol-
ogy, CA, USA) at 1:100 dilution at room temperature for
1 h and MIB-1 monoclonal antibody (Immunotech, Mar-
seille, France) at 1:100 dilution for 12 h at room temper-
ature. Coloration was performed using diaminobenzidine
(Bio-Genex, San Ramon, CA, USA).
MIB-1 value was determined counting 1,000 epithelial
cells in ten randomly selected fields by a standard light
microscope with an oil immersion objective (magnification
1,0009) and the results were expressed as a percentage of
positive cells. For ceramide expression, tissue sections
were treated with 3 % (v/v) hydrogen peroxide in water, to
quench endogenous peroxidase, and incubated overnight
with mouse monoclonal antibody anti-ceramide (clone
MID 15B4, Alexis Biochemicals, working dilution 1:10 in
PBS). Immune reaction was revealed by indirect immunop-
eroxidase method (Vectastain Elite kit, Vector, Burlingame,
CA, USA), using 3,30-diaminobenzidine as chromogen. As
negative controls, sections incubated with only the primary
or the secondary antisera were used. In each section, the
number of ceramide positive cells were counted in ten
randomly chosen microscopical fields at a 2009 final
magnification (test area, 72,346 lm2).
Two of the authors (L.M. and D.B.) independently
evaluated the immunostained specimens.
The extent of immunostaining for COX-2 was recorded
semi-quantitatively. For this purpose staining of HT29
colon cancer cell line was considered as 100 % [16]. Study
specimens staining was graded using a 3-grade system,
based on the percentage of stained tumour epithelial cells:
grade 0 = 1–20 %; grade 1 = 21–70 %; grade 2 = more
than 70 % [17].
Mucosal Cell Cultures and Drugs
Samples were cultured as described by Shirvani et al. [12].
Briefly, mucosal biopsy specimens were placed on a ster-
ilized stainless wire mesh within a Falcon center-well
organ culture dish (DB Biosciences, NJ, USA) so that 1 ml
of cultured medium just covered the surface of the biopsy.
Organ culture dishes were then placed on racks in an
incubator chamber oxygenated with 95 % O2 and 5 % CO2
at 37 "C. Cell culture was performed in RPMI 1640 sup-
plemented with 10 % fetal calf serum in the presence of
glutamine (2 mM), glucose (3.66 mg/mL), 500 units/mL
streptomycin, and 250 units of penicillin. Mucosal biopsies
were first equilibrated in the culture medium for 2 h, then
washed twice and cultured in a fresh medium for further
24 h and finally utilized for the experiments. Deoxycholic
acid (DCA) and epidermal growth factor (EGF) were
purchased from Sigma (St. Louis, MO, USA); celecoxib
was kindly provided by Monsanto (St. Louis, MO, USA).
Cell Viability Assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrasolium
bromide (MTT) assay was used to determine cell viability.
MTT is a yellow-coloured tetrazolium salt that is taken up
and cleared only by metabolically active cells, which
reduce it to a coloured, water-insoluble formasan salt. The
solubilized formasan product is quantified via absorbance
at 750 nm, which is measured using a 96-well-format
spectrophotometer. The absorbance correlates directly with
the cell number. The basal viability of the cells obtained
from the tissue fragment was 85–88 %. A significant loss
in cell viability was only observed after the treatment both
with DCA and celecoxib at concentrations [25 lmol/L.
Therefore, the experiments were done using non cytotoxic
doses of drugs (1 lmol/L).
Cell Proliferation Assay
Cell proliferation was determined by the 3[H]-thymidine
incorporation assay in order to evaluate DNA synthesis.
Briefly, cells from esophageal biopsy cultures were seeded
in 24-well plates and maintained in DMEM medium for
Dig Dis Sci (2014) 59:949–957 951
123
24 h. After a 24-h incubation at 37 "C in a 5 % CO2
atmosphere in steady-state medium (i.e. medium supple-
mented with 1 % FCS), the culture medium was replaced
with 200 lL fresh culture medium containing 10 % FCS,
with or without 1 lM DCA or 1 lM EGF. Cells cultured
solely in media served as negative controls. After 24 h of
incubation the cells were pulsed for 4 h with
methyl-3[H] thymidine, 0.5 lCi per well (Amersham, UK;
specific activity, 50 Ci/mmol).
The medium was then removed and DNA was precipi-
tated with cold 3 % trichloroacetic acid and extracted with
1 mL of 0.3 N NaOH. The recovered radioactivity was
measured in a b-counter (model 1900 TR; Packard Tricarl,
Zurich, Switzerland). The experiments, when possible,
were performed in duplicate and the values expressed as
pmol/lg protein (mean ± SE).
COX-2 and VEGF Protein Expression
Tissue samples were processed as described previously
[16]. The samples were mixed 1:1 with sample buffer/
20 mmol/L Tris–HCl, pH 6.8, 20 % glycerol, 2 % sodium
dodecyl sulphate (SDS), 5 % b-mercaptoethanol, and
0.025 % bromphenol blue. SDS-polyacrylamige gel elec-
trophoresis (PAGE) was performed using 8 and 5 %
acrylamide for the separating gel and the staking gel,
respectively. Proteins were transferred onto nitrocellulose
membranes (Pierce, Chemical Co., IL, USA). Blots were
blocked with bovine serum albumin 5 % in PBS (Pierce
Chemical Co., IL, USA) and incubated overnight at 4 "C
with human anti COX-2 and anti VEGF goat polyclonal
antibodies and anti COX-1 monoclonal antibodies (Cay-
man Chemical Co., MI, USA) at 1:1,000 dilution; goat
polyclonal anti-actin antibody (1:100, Santa Cruz Bio-
technology, CA, USA) was used as standard. Blots were
additionally incubated with secondary antibodies conju-
gated with horseradish peroxidase (1:5,000, Amersham,
UK) for 2 h at room temperature and, finally, incubated
with SuperSignal West Pico Chemiluninescent Substrate
(Pierce, Chemical Co., IL, USA) for 5 min and then
exposed to CL-X exposure film (Pierce, Chemical Co., IL,
USA).
Prostaglandin E2 (PgE2) and Vascular Endothelial
Growth Factor (VEGF) Production
Supernatants (100 lL each) were utilized for PGE2 and
VEGF determination using competitive enzyme immuno-
assay kits (Cayman Chemical Co, Ann Arbor, MI, USA)
according to methods previously described (Cianchi et al.
[8]). Celecoxib, 1 lmol/L, was added 30 min before add-
ing EGF or DCA at 1 lM concentration. After 24 h of
incubation, the supernatants were collected and prepared
according to the method described previously [16].
Determinations were performed in duplicate. PGE2 and
VEGF values were expressed as pg per mg and lg protein,
respectively.
Protein concentration was determined according to the
method described by Lowry et al. [18]; bovine serum
albumin (BSA) was used as standard.
Determination of Caspase-3 Activity
The activity of caspase-3 (an index of cell susceptibility to
apoptosis) was determined by the use of a fluorescent
substrate following Stennicke and Salvesen [19]. The
Ac-Asp-Glu-Val-Asp-AMC (AC-DEVD-ANC; Bachen)
was used as a fluorescent substrate for caspase-3 [20].
Briefly, the frozen tissue samples were homogenized
with 10 mM N-2-hydroxymethylpiperazine-N-2-ethansulf-
one acid (HEPES, pH 7.4) containing 0.5 % [(3-cholami-
dopropyl) dimethylammino]-1-propane-sulfonate (CHAPS),
42 mM KCl, 5 mM NaCl2, 1 mM dithiothreitol (DTT),
1 mM phenylmethylsulfonyl fluoride (PMSF), 2 lg/mL
leupeptin and 1 lg/mL pepstatin A.
The homogenate was then centrifuged at 10,000g for
10 min. The activity of caspase-3 was determined in the
supernatant by fluorometric assay using the substrate,
AC-DEVD-AMC. Supernatant (containing about 70–80 lg
total protein) was incubated with 40 lM of the caspase-3
substrate AC-DEVD-AMC for 60 min at 37 "C. At the end
of incubation, substrate cleavage was monitored fluoro-
metrically with a k excitation at 380 nm and k emission at
460 nm. Data are expressed as arbitrary mU/lg proteins.
One unit of enzyme activity is defined as the amount of
enzyme required to liberate 40 lmol of AC-DEVD-AMC
for 60 min at 37 "C.
Statistical Analysis
The values were expressed as mean ± standard error (SE).
Statistical analysis was done using GraphPad Prism Sta-
tistic (release 5.0; GraphPad Software Inc. CA, USA) using
ANOVA analysis. P-values were calculated with the use of
either one- or two-sided statistical tests, when not other-
wise specified the one-way test was used; p\ 0.05 was
considered statistically significant.
Results
Patients
On the basis of the histopathologic findings of the endo-
scopic biopsy samples, four groups of symptomatic
patients were distinguished: (1) five non esophagitis, (2)
952 Dig Dis Sci (2014) 59:949–957
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11 non erosive esophagitis, (3) 11 erosive esophagitis, and
(4) six BE (Table 1). Moreover, five patients undergoing
endoscopy without symptoms and any endoscopic findings
of GER were studied and considered as controls.
COX-1 and COX-2 Expression and PGE2 Production
COX-2 expression in the biopsies, detected by Western
blotting (relative molecular weight 72 kD), showed an
increasing trend with the progression of the disease,
whereas COX-1 expression (relative molecular weight
66 kD) is not different in the four groups (Fig. 1, panel A).
COX-2 staining increased with the stage of the disease;
the mean values (± SE) of COX-2 grading of immuno-
staining are indicated in Fig. 1, panel B.
Basal PGE2 production gradually increased accordingly
with the progression of the disease, indicating a relevant
COX-2 activation in erosive esophagitis and BE. PGE2
basal values were significantly different in BE and erosive
esophagitis groups when compared to non esophagitis
patients and controls (p\ 0.05) (Fig. 1, panel C).
A significant enhancement of PGE2 in the supernatants
is observed in each group after 24-h incubation of the cells
with 1 lM DCA when compared to basal levels
(p\ 0.001, two-way ANOVA). The pre-incubation of the
cells for 60 min with 1 lM celecoxib, a COX-2 selective
inhibitor, prevented DCA-mediated increase in PGE2 pro-
duction (Fig. 1, panel C). The latter finding supports COX-
2 as the main source of PGE2 after DCA stimulation.
Cell Proliferative Activity
3[H]-thymidine incorporation showed an increasing trend
accordingly with the stage of the disease. Basal levels of
thymidine incorporation in BE was significantly different
when compared to controls and the non esophagitis group
(p\ 0.01) (Fig. 2, panels A and B).
Twenty-four hour incubation of the cells both with DCA
(1 lM) (Fig. 2, panel A) or EGF (1 lM) (Fig. 2, panel B)
significantly stimulated the incorporation of 3[H]-thymi-
dine in all the groups (p\ 0.01 when compared with the
respective basal values). Pretreatment with 1 lM celecoxib
did not affect the basal levels of 3[H]-thymidine incorpo-
ration, as reported in Fig. 2, whereas it almost completely
prevented the effects of the two proliferative stimuli,
confirming the COX-2 role in the enhancement of cell
proliferation due both to DCA and EGF (Fig. 2, panels A
and B).
MIB-1 was significantly over-expressed in non erosive,
erosive esophagitis and BE patients when compared to
controls and non esophagitis patients (*p\ 0.05,
**p\ 0.01 and ***p\ 0.001 respectively) and gradually
increased accordingly with the severity of the disease
(Fig. 3, panels A and B).
These findings support the above-mentioned results
concerning 3[H]-thymidine incorporation and confirm a
link between the progression of the disease and cell
proliferation.
VEGF Protein Expression and VEGF Production
The expression of VEGF correlated with the stage of the
disease. In fact, both protein expression and VEFG pro-
duction increased with the progression of the disease
(Fig. 4, panels A and C, respectively). The production of
Fig. 1 Western blot analysis of COX-2 and COX-1 proteins in
human specimens from controls, non esophagitis, non erosive and
erosive esophagitis and BE patients. The samples were normalized
with b-actin (a). The grading of COX-2 (b) showed significant
differences (*p\ 0.05) both in erosive esophagitis and BE patients
when compared to controls and non esophagitis patients. COX-2
activity, evaluated as PGE2 production (mean values ± SEM) in the
supernatant of tissue fragments before (basal) and after 24 h
incubation with 1 lM DCA (c). DCA incubation significantly
increased PGE2 production with significant differences when com-
pared to basal levels in all the groups (two-way ANOVA,
**p\ 0.01). Celecoxib pre-incubation (1 lM) for 1 h reverted
PGE2 production to basal levels in all the groups (two-way ANOVA,
##p\ 0.01)
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VEGF in non erosive, erosive esophagitis and BE was
significantly different from both controls and non esopha-
gitis patients. Again pre-treatment of the cells with 1 lM
celecoxib prevents the DCA-induced increase in VEGF
production (Fig. 4, panel C).
Caspase-3 Activity and Ceramide Expression
as an Index of Apoptosis
Caspase-3 activity progressively decreased from non
esophagitis to BE (Fig. 5, panel A), suggesting a pro-
gressively increasing impairment of the apoptotic pro-
cess with the progression of the disease. When BE
mucosal biopsies were cultured in the presence of 1 lM
celecoxib the activity of caspase-3 increases from 169.
75 ± 27 to 295.38 ± 42 mU/lg protein (p\ 0.01). This
finding confirms the pro-apoptotic effect of COX-2
inhibitors and a role for COX-2 through the inhibition
of apoptosis in BE. The results of the assessment of
ceramide expression are shown in Fig. 5, panel B. The
number of ceramide positive cells increased from non
esophagitis to non erosive and erosive esophagits, but it
was low in BE.
Discussion
Our results clearly demonstrate the involvement of COX-2
in the pathogenesis of the reflux-related earliest histologi-
cal modifications and therefore in the initial steps of the
esophageal adenocarcinogenetic pathway. This datum
represents a novelty in man and may have some important
clinical implications.
It is well established that COX-2 plays a relevant role
both in inflammatory and tumorigenic processes [21].
Whereas its mechanisms of action have been well eluci-
dated for inflammation, less is known for cancer promo-
tion. Some experimental studies demonstrated that COX-2
over-expression is associated with a significant decrease of
apoptosis, an increase in malignant cell invasiveness and an
enhancement of prostaglandin synthesis and cell prolifer-
ation [22]. Opposite effects together with decreased angi-
ogenesis are associated with COX-2 inhibition [23].
Both the proinflammatory and tumorigenic effects may
contribute to explain why COX-2 has been considered
involved in esophageal, gastric and colorectal carcinogen-
esis [24]. More specifically, as far as esophageal carcino-
genesis is concerned, some epidemiological studies have
suggested that COX-2 inhibitors play a protective effect,
which may take place early in the inflammation-metapla-
sia-carcinoma sequence (i.e. before the occurrence of BE
and even before the occurrence of esophagitis) [25].
On the contrary, results of clinical studies in BE appear
to some extent conflicting. On one hand, 10-day therapy
with specific COX-2 inhibitors reduced COX-2 expression,
PGE2 release and cell proliferation [26]; on the other hand,
no differences in the progression of BE dysplasia to cancer
seems to be produced by 48-week treatment with celecoxib
[27].
More consistent data are produced by experimental
findings which showed a reduction of both inflammation
and tendency to develop adenocarcinoma induced by
COX-2 inhibitors administration in rat [13].
In the present study, COX-2 expression, proliferative
activity, VEGF expression/production and basal PGE2
levels in esophageal biopsies progressively increase from
patients without esophagitis to patients with non erosive
and erosive esophagitis, to those with BE. Incubation of the
cells with DCA determines a PGE2 production increase,
which is prevented by pretreatment with the selective
COX-2 inhibitor celecoxib. This inhibitory effect of cele-
coxib also takes place on both DCA/EGF stimulated pro-
liferative activity and VEGF production.
Fig. 2 3[H] thymidine incorporation in all studied groups (a, b). The
basal and both DCA- (a) and EGF- (b) stimulated proliferative
activity increased with the progression of the disease. Differences
were significant between each group and the preceding one (two-way
ANOVA, **p\ 0.001). Pre-treatment of the cells with celecoxib
significantly inhibited proliferation induced by DCA or EGF (two-
way ANOVA, ##p\ 0.001)
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Therefore, our data are in agreement with previous
reports and complete previous findings, showing a COX-2
involvement even in the early steps of the sequence leading
to esophageal adenocarcinoma.
From previous epidemiological, experimental and clin-
ical findings and from the present data a unitary interpre-
tation of the effects of COX-2 inhibition on the esophageal
progression from normal epithelium to BE and further to
adenocarcinoma could be proposed. First of all, COX-2
inhibition could generically exert an anti-inflammatory
effect throughout the process. Moreover, at a very early
stage it may interfere with the progression of the sequence,
due to the prevention of the pro-inflammatory and angio-
genetic effects of PGE2. This could downstage esophagitis
and, consequently, prevent and/or slow-down intestinal
metaplasia formation. Once intestinal metaplasia has
occurred, it is likely that no reversion effect on it can be
exerted by COX-2 inhibition, and for this item results of
the ASPECT trial will be decisive. On the other hand,
COX-2 inhibition could probably be relevant in avoiding or
slowing-down the further step, i.e. the progression of
metaplasia to dysplasia. Moreover, although dysplasia has
probably an unavoidable tendency for further development
to adenocarcinoma [28], this evolution could be restrained
Fig. 3 Immuno-histochemistry
expression of Mib-1 in human
specimens from controls, non
esophagitis, non erosive, erosive
esophagitis and BE patients
(a, b). Mib-1 gradually
increased with the severity of
the disease (significant
differences of non erosive,
erosive esophagitis and BE both
versus controls and non
esophagitis patients (*p\ 0.05;
**p\ 0.01; ***p\ 0.001,
respectively)
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by the inhibition of the antiapoptotic and cell proliferation
promoting activities of COX-2.
Sphingolipids have been recently shown to be sources of
important signaling molecules. Particularly the sphingo-
lipid metabolites, ceramide and sphingosine-1-phosphate
have emerged as a new class of potent bioactive molecules
implicated in inflammation, cell proliferation and apoptosis
regulation [29]. The ‘‘de novo’’ synthetic pathway of
intracellular ceramide can be elicited by a few different
stimuli among which also inflammatory conditions, such as
esophagitis, are represented.
It has been recently demonstrated that spinal formation
of ceramide determines neuroimmune activation, nitrosa-
tive stress and increased apoptosis [29, 30].
In our study ceramide positive cells gradually
increase from non erosive esophagitis to erosive
esophagitis patients. This finding is in line with previous
experimental data [29–32]. On the contrary, in our BE
patients ceramide levels were significantly lower than in
non erosive and erosive esophagitis and similar to those
in controls and non esophagitis patients. The latter
finding is hardly explainable, even considering BE as a
complex condition in which a multifactorial impairment
of different pro-inflammatory and apoptotic pathways
are involved [14].
In conclusion, although further studies and larger series
are needed, our findings of a close relationship between
progression of GERD from its very initial steps and COX-
2, proliferative activity and EGF/VEGF expression might
have important implications in the strategy of management/
treatment of GERD in order to prevent its neoplastic
evolution.
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Fig. 4 Western blot analysis of VEGF protein in human specimens
from controls, non esophagitis, non erosive, erosive esophagitis and
BE patients. Samples were normalized with b-actin (a). The
expression of VEGF increased from non erosive and erosive
esophagitis to BE patients (b). The basal and DCA-stimulated VEGF
production gradually increased with the stage of the disease
(*p\ 0.01). Celecoxib pre-incubation (1 lM) for 1 h reduced DCA
stimulated VEGF production in non erosive and erosive esophagitis
and BE patients compared with controls and non esophagitis patients
(c) (two-way ANOVA, #p\ 0.05)
Fig. 5 a The activity of caspase-3 progressively decreased from non
esophagitis to BE patients (*p\ 0.05; **p\ 0.01; ***p\ 0.001
among groups). The number of positive cells of ceramide (b) was
significantly greater in non erosive and erosive esophagitis in
comparison to controls and non esophagitis patients (*p\ 0.05;
**p\ 0.01). No differences were shown between BE and both
controls and non esophagitis (b)
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